Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Metabolism as a key to histone deacetylase inhibition.

Rajendran P, Williams DE, Ho E, Dashwood RH.

Crit Rev Biochem Mol Biol. 2011 Jun;46(3):181-99. doi: 10.3109/10409238.2011.557713. Epub 2011 Apr 5. Review.

2.

Histone deacetylase inhibitors: a review on class-I specific inhibition.

Behera J, Jayprakash V, Sinha BN.

Mini Rev Med Chem. 2015;15(9):731-50. Review.

PMID:
25994050
3.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
4.

The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.

Choi SE, Pflum MK.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7084-6. doi: 10.1016/j.bmcl.2012.09.093. Epub 2012 Oct 2.

5.

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.

Khan O, La Thangue NB.

Immunol Cell Biol. 2012 Jan;90(1):85-94. doi: 10.1038/icb.2011.100. Epub 2011 Nov 29. Review.

PMID:
22124371
6.

Inhibitors of histone deacetylase as new anticancer agents.

Jung M.

Curr Med Chem. 2001 Oct;8(12):1505-11. Review.

PMID:
11562279
7.

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.

Dedes KJ, Dedes I, Imesch P, von Bueren AO, Fink D, Fedier A.

Anticancer Drugs. 2009 Jun;20(5):321-33. doi: 10.1097/CAD.0b013e3283262a32.

PMID:
19322073
8.

Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.

Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D.

J Nutr Biochem. 2008 Sep;19(9):587-93. Epub 2007 Dec 3.

PMID:
18061431
9.

Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.

Cho M, Choi E, Yang JS, Lee C, Seo JJ, Kim BS, Oh SJ, Kim HM, Lee K, Park SK, Kwon HJ, Han G.

ChemMedChem. 2013 Feb;8(2):272-9. doi: 10.1002/cmdc.201200529. Epub 2013 Jan 4.

PMID:
23292995
10.

Dietary histone deacetylase inhibitors: from cells to mice to man.

Dashwood RH, Ho E.

Semin Cancer Biol. 2007 Oct;17(5):363-9. Epub 2007 May 5. Review.

11.

A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.

Myzak MC, Karplus PA, Chung FL, Dashwood RH.

Cancer Res. 2004 Aug 15;64(16):5767-74.

12.

Biomarkers for predicting clinical responses to HDAC inhibitors.

Stimson L, La Thangue NB.

Cancer Lett. 2009 Aug 8;280(2):177-83. doi: 10.1016/j.canlet.2009.03.016. Epub 2009 Apr 10. Review.

PMID:
19362413
13.

The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

Choi SE, Weerasinghe SV, Pflum MK.

Bioorg Med Chem Lett. 2011 Oct 15;21(20):6139-42. doi: 10.1016/j.bmcl.2011.08.027. Epub 2011 Aug 12.

14.

Histone deacetylase inhibitors: current status and overview of recent clinical trials.

Ma X, Ezzeldin HH, Diasio RB.

Drugs. 2009 Oct 1;69(14):1911-34. doi: 10.2165/11315680-000000000-00000. Review.

PMID:
19747008
15.

Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.

Thaler F.

Pharm Pat Anal. 2012 Mar;1(1):75-90. doi: 10.4155/ppa.11.3. Review.

PMID:
24236715
16.

Histone deacetylase inhibitors: the Abbott experience.

Curtin M, Glaser K.

Curr Med Chem. 2003 Nov;10(22):2373-92. Review.

PMID:
14529480
17.

A cyclodextrin-capped histone deacetylase inhibitor.

Amin J, Puglisi A, Clarke J, Milton J, Wang M, Paranal RM, Bradner JE, Spencer J.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3346-8. doi: 10.1016/j.bmcl.2013.03.084. Epub 2013 Apr 2.

PMID:
23591111
18.

HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.

Rajendran P, Kidane AI, Yu TW, Dashwood WM, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.

Epigenetics. 2013 Jun;8(6):612-23. doi: 10.4161/epi.24710. Epub 2013 Apr 26.

19.

Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer.

Hede K.

J Natl Cancer Inst. 2006 Mar 15;98(6):377-9. No abstract available.

20.

Targeting histone deacetylases: development of vorinostat for the treatment of cancer.

Richon VM.

Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20. Review.

PMID:
22121904
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk